NASDAQ:AIMT AIMMUNE THERAPEUTICS INC
AIMT formed a classic cup-with-handle IPO base, and eclipsed its buy point at $26.08 on a huge spike in on September 30. The breakout failed the very next day. Still basing. A downside break of $18.47 (the Aug 24 low) would set up a larger double-bottom base.